Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_assertion type Assertion NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_head.
- NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_assertion description "[From the initial proof of concept study with the PARP1 inhibitor olaparib (AZD2281) in BRCA mutation carriers, in which 28% of ovarian cancer patients achieved an objective response, the target population of ovarian patients potentially sensitive to treatment with PARP inhibitors has greatly increased.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_provenance.
- NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_assertion evidence source_evidence_literature NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_provenance.
- NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_assertion SIO_000772 22180407 NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_provenance.
- NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_assertion wasDerivedFrom befree-20140225 NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_provenance.
- NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_assertion wasGeneratedBy ECO_0000203 NP259413.RA1LX6bnORQ5aolXRshy45CTpGsfXq01A4CBu06rZnoOI130_provenance.